Clinical trials: Advanced Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma (RCC)
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
This study is a multicenter, open-label, randomized controlled trial that enrolled 116 patients with advanced or metastatic renal cell carcinoma who had failed first-line treatment with PD-1/PD-L1 monotherapy or VEGFR TKI…
- Trial name
- NCT07165418
- Testing
- Vorolanib Tablets+Everolimus, Sunitinib
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Peking University Cancer Hospital & Institute
Kidney Cancer
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
RATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. It may also stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00096525
- Testing
- lenalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Endometrial Cancer
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00659568
- Testing
- metformin hydrochloride, temsirolimus
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer)
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are…
- Conditions
- Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
- Trial name
- NCT05873686
- Testing
- NXP900
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Nuvectis Pharma, Inc.
Carcinoma, Renal Cell, Glioblastoma
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority of patients will eventually…
- Conditions
- Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular
- Trial name
- NCT01441388
- Testing
- Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib
- Sponsor
- Pfizer
Renal Cell Carcinoma
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
A retrospective medical record abstraction study of at least 200 advanced renal cell carcinoma patients treated in the following settings: Patients with advanced renal cell carcinoma treated with Sorafenib (Nexavar) as…
- Trial name
- NCT00876382
- Where
- 8 sites in United States
- Volunteers
- 47 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Renal Cell Carcinoma
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
The principal aim of the study is to determine the objective response rate that offers the second-line treatment with pazopanib in patients with carcinoma of advanced renal cells that have progressed or that have not tolerated…
- Trial name
- NCT01577784
- Testing
- Pazopanib
- Where
- 10 sites in Spain
- Volunteers
- 27 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Cancer, Immunotherapy
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or…
- Conditions
- Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
- Trial name
- ELEPHAS-05 (NCT07327489)
- Testing
- Biopsy
- Where
- 8 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Elephas
Carcinoma, Renal Cell, Kidney Neoplasms
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 [Temsirolimus], administered intravenously [IV] once weekly and…
- Trial name
- ARCC (NCT00065468)
- Testing
- Interferon Alfa, CCI-779, Interferon Alfa and CCI-779
- Where
- 153 sites in United States, Argentina and 23 more
- Volunteers
- 626 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Advanced Renal Cell Carcinoma
Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
This study evaluated the safety and efficacy of SHR-8068 in combination anti-tumor drugs in the treatment of advanced renal cell carcinoma
- Trial name
- NCT07239596
- Testing
- SHR-8068；Adebrelimab ；Bevacizumab, SHR-8068 ; SHR-4610
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Advanced or Metastatic Renal Cell Carcinoma, Renal Cancer
Study In Patients With Kidney Cancer Treated With Sutent
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
- Trial name
- NCT00873210
- Testing
- Sutent
- Where
- 14 sites in Slovakia
- Volunteers
- 121 people
- Sponsor
- Pfizer
Renal Cancer
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
It is a phase II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0025 in patients with advanced clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT06222125
- Testing
- HB0025
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Carcinoma, Renal Cell
Study of SU011248 in Patients With Advanced Kidney Cancer
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).
- Trial name
- NCT00254540
- Testing
- SU011248 capsule
- Where
- 11 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa.
- Trial name
- INTORACT (NCT00631371)
- Testing
- Bevacizumab, Temsirolimus, Interferon-Alfa 9MU
- Where
- 172 sites in United States, Argentina and 28 more
- Volunteers
- 791 people
- Sponsor
- Pfizer
Kidney Cancer, Metastatic Cancer
Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or bevacizumab, and allow doctors to plan better…
- Trial name
- NCT01105364
- Testing
- antiangiogenesis therapy, stabilized sulphur hexafluoride microbubble-based contrast agent, imaging biomarker analysis
- Where
- France
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute, France
Renal Cell Carcinoma
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
- Trial name
- NCT04088500
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Clear Cell Renal Cell Carcinoma
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell…
- Trial name
- NCT04169711
- Testing
- ARO-HIF2
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Arrowhead Pharmaceuticals